[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-tumors-andor-solid-tumors-including\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-tumors-andor-solid-tumors-including":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100625277","clinical-significance-of-liquid-biopsy-in-brain-tumor-patients-a-5-ala-guided-approach-100625277",false,"NCT07420543","Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach","FLUO-LB","Inclusion Criteria:\n\n* Inclusion Criteria (Glioblastoma Patients):\n* Patient aged 18 years or older\n* Diagnosis of supratentorial glioblastoma at its first occurrence (Grade 4, WHO 2021), confirmed through histological analysis, in a brain area that is accessible for surgical removal.\n* Ability of the patient to give informed consent.\n* Suitability for surgery with fluorescence guidance using 5-ALA.\n\nInclusion Criteria (Other Brain Tumors):\n\n* Patient aged 18 years or older\n* Ability of the patient to give informed consent.\n* Suitability for surgery with fluorescence guidance using 5-ALA.\n\nExclusion Criteria:\n\nExclusion Criteria (Glioblastoma Patients):\n\n* Presence of other systemic tumors.\n* Known allergic sensitivity or contraindications to gadolinium.\n* Contraindications to MRI, such as the presence of non-compatible implanted devices.\n* Significantly compromised renal function (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²), and\u002For patients undergoing dialysis.\n* Conditions that contraindicate surgery with fluorescence guidance using 5-ALA.\n\nExclusion Criteria (Other Brain Tumors):\n\n* Patients suffering from systemic tumors (besides the primary of the brain metastasis).\n* Individuals with known allergies or adverse reactions to gadolinium.\n* Individuals with contraindications for MRI, including those with implants not compatible with the procedure.\n* Individuals with significantly reduced kidney function (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²), or those undergoing dialysis.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up, and as a prognostic tool in patients with GBM.",[24,25,26,27],"Brain Tumors and\u002For Solid Tumors Including","Glioblastoma","Glioblastoma (GBM)","Glioblastoma - Category",[26,25,29,30,31,32,33],"Liquid Biopsy","GBM","5-ALA","Protoporphyrin IX (PpIX)","Fluorescence","RECRUITING","2026-02-11",{"date":37,"type":38},"2026-02-19","ACTUAL",{"date":40,"type":38},"2017-01-18",{"date":42,"type":20},"2027-05",{"name":44,"class":45},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","OTHER"]